107 related articles for article (PubMed ID: 38839335)
1. Sustained Clinical Complete Response after Discontinuation of Trastuzumab-deruxetecan Due to Interstitial Pneumonia for HER2-positive Gastric adenocarcinoma with Enteroblastic Differentiation (GAED): A Case Report.
Suzuki N; Odawara N; Fujisawa G; Ishibashi R; Hata M; Oya Y; Tamada K; Hayashi T; Abe S; Miyakawa Y; Hayakawa Y; Shinozaki-Ushiku A; Ushiku T; Boku N; Fujishiro M
Intern Med; 2024 Jun; ():. PubMed ID: 38839335
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Third-Line Trastuzumab Deruxtecan in a Patient with De Novo Stage 4 HER2-Positive Gastric Adenocarcinoma with Enteroblastic Differentiation: A Case Report.
Ngan RK
Life (Basel); 2023 Aug; 13(9):. PubMed ID: 37763255
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma.
Kang C
Target Oncol; 2023 Nov; 18(6):981-989. PubMed ID: 37787931
[TBL] [Abstract][Full Text] [Related]
4. Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report.
Ogata T; Fujita Y; Muro K
Am J Case Rep; 2022 Mar; 23():e935600. PubMed ID: 35241641
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-Gastric01 study.
Shitara K
Future Oncol; 2024 Jan; 20(2):59-70. PubMed ID: 37916503
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study.
Shitara K; Yamaguchi K; Muro K; Yasui H; Sakai D; Oshima T; Fujimura M; Sato Y; Yamazaki S; Wakabayashi T; Sugihara M; Kamio T; Shoji H
Int J Clin Oncol; 2024 Jan; 29(1):27-35. PubMed ID: 37964066
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
Yamaguchi K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Lee J; Shimoyama T; Lee KW; Saito K; Kawaguchi Y; Kamio T; Kojima A; Sugihara M; Shitara K
J Clin Oncol; 2023 Feb; 41(4):816-825. PubMed ID: 36379002
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Lee J; Saito K; Kawaguchi Y; Kamio T; Kojima A; Sugihara M; Yamaguchi K;
N Engl J Med; 2020 Jun; 382(25):2419-2430. PubMed ID: 32469182
[TBL] [Abstract][Full Text] [Related]
9. [Gastric adenocarcinoma with enteroblastic differentiation and elevated serum alpha fetoprotein].
Li QZ; Zhao HB; Ban N; Wang Q; Zhang JJ; Ding SN; Li HH; Zhou ZH
Zhonghua Bing Li Xue Za Zhi; 2020 Sep; 49(9):886-890. PubMed ID: 32892552
[No Abstract] [Full Text] [Related]
10. Next-generation sequencing analysis for gastric adenocarcinoma with enteroblastic differentiation: emphasis on the relationship with hepatoid adenocarcinoma.
Akazawa Y; Saito T; Hayashi T; Yanai Y; Tsuyama S; Akaike K; Suehara Y; Takahashi F; Takamochi K; Ueyama H; Murakami T; Watanabe S; Nagahara A; Yao T
Hum Pathol; 2018 Aug; 78():79-88. PubMed ID: 29751042
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics of gastric adenocarcinoma with enteroblastic differentiation and gastric adenocarcinoma with enteroblastic marker expression.
Abe D; Akazawa Y; Yatagai N; Hayashi T; Ueyama H; Mine S; Fukunaga T; Nagahara A; Yao T; Saito T
Virchows Arch; 2023 Sep; 483(3):405-414. PubMed ID: 37581693
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.
Van Cutsem E; di Bartolomeo M; Smyth E; Chau I; Park H; Siena S; Lonardi S; Wainberg ZA; Ajani J; Chao J; Janjigian Y; Qin A; Singh J; Barlaskar F; Kawaguchi Y; Ku G
Lancet Oncol; 2023 Jul; 24(7):744-756. PubMed ID: 37329891
[TBL] [Abstract][Full Text] [Related]
13. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.
Kumagai K; Aida T; Tsuchiya Y; Kishino Y; Kai K; Mori K
Cancer Sci; 2020 Dec; 111(12):4636-4645. PubMed ID: 33051938
[TBL] [Abstract][Full Text] [Related]
14. Twenty-four-month Progression-free Survival in HER2-amplified Advanced Gastric Cancer with Brain Metastases after Trastuzumab Deruxtecan Treatment: A Case Report and Literature Review.
Zhang H; Xu M
Curr Cancer Drug Targets; 2024 Mar; ():. PubMed ID: 38465434
[TBL] [Abstract][Full Text] [Related]
15. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective.
Aoki M; Iwasa S; Boku N
Gastric Cancer; 2021 May; 24(3):567-576. PubMed ID: 33646464
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and immunohistochemical characteristics of gastric adenocarcinoma with enteroblastic differentiation: a study of 29 cases.
Murakami T; Yao T; Mitomi H; Morimoto T; Ueyama H; Matsumoto K; Saito T; Osada T; Nagahara A; Watanabe S
Gastric Cancer; 2016 Apr; 19(2):498-507. PubMed ID: 25893262
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer.
Kotani D; Shitara K
Ther Adv Med Oncol; 2021; 13():1758835920986518. PubMed ID: 33473250
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
Mishima S; Shitara K
Expert Opin Biol Ther; 2021 Jul; 21(7):825-830. PubMed ID: 33798395
[No Abstract] [Full Text] [Related]
20. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
Rugo HS; Crossno CL; Gesthalter YB; Kelley K; Moore HB; Rimawi MF; Westbrook KE; Buys SS
JCO Oncol Pract; 2023 Aug; 19(8):539-546. PubMed ID: 37207306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
